Hong Kong
· Delayed Price · Currency is HKD Biocytogen Pharmaceuticals (Beijing) Company Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally.
Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors.
The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors.
In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules.
The company has collaboration with Syncromune, Inc.; out license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences; and collaboration with Acepodia Inc. for development of dual-payload bispecific antibody-drug conjugates.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is headquartered in Beijing, China.
| Country | China |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,117 |
| CEO | Yuelei Shen |
Contact Details
Address: 12 Baoshen South Street Beijing China | |
| Phone | 86 10 5696 7680 |
| Website | biocytogen.com.cn |
Stock Details
| Ticker Symbol | 2315 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100005D27 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Qingcong Lin | Deputy GM and Chief Executive Officer of Biocytogen Boston Corporate |
| Dr. Yuelei Shen Ph.D. | Chairman of the Board, Chief Executive Officer and GM |
| Dr. Jian Ni | Executive Director |
| Dr. Haichao Zhang | Senior Operation Director of Animal Center and Executive Director |
| Bin Liu | Chief Financial Officer and Deputy GM |
| Dr. Yi Yang | Chief Scientific Officer and Deputy GM |
| Dr. Chaoshe Guo | Vice President of Marketing and Deputy GM |
| Chunli Sun | Director of Human Resources and Supervisor |
| Yan Li | Chairman of the Supervisory Committee and Director of the President's Office |
| Yongliang Wang | Deputy GM, Joint Company Secretary and Chief Secretariat Officer |